Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Fourth mRNA COVID-19 vaccine immunogenic, safe
Mar 24, 2022
Vaccine efficacy 30% for BNT162b2(Pfizer) and 11 percent for mRNA-1273 (Moderna) against any SARS-CoV-2 infection.
Risk for shoulder conditions small after vaccination in deltoid muscle
Mar 21, 2022
The incidence of shoulder conditions per 10,000 vaccinations was 1.22 for adults (age 18 years or older) and 0.05 for children (age 3 to 17 years).
Moderna asks FDA to approve second booster for all adults
Mar 18, 2022
The Moderna request covers all adults to give federal health officials the freedom to determine who should get a second booster.
Risk for blood clots after COVID-19 vaccination explored
Mar 11, 2022
Two studies show an increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1-S.
Vaccination ups infection-acquired immunity against SARS-CoV-2
Mar 01, 2022
Two doses of the BNT162b2 (Pfizer-BioNTech) vaccine were linked to high short-term protection against infection, which wanes after six months.
COVID-19 vaccination tied to decline in distress in U.S. adults
Feb 24, 2022
Decreases in distress and perceived risks for infection, hospitalization and death were reported by those receiving at least one dose of the vaccine.
Low risk seen for second allergic reaction to mRNA COVID-19 vaccine
Feb 22, 2022
Of 1,366 patients with an immediate allergic reaction to the first dose, six developed a severe immediate allergic reaction after the second dose.
Homologous, heterologous COVID-19 boosters are immunogenic
Feb 07, 2022
Antibody neutralizing titers against SARS-CoV-2 D614G pseudovirus increased by a factor of 4 to 73 for all combinations.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.